New results from translational, clinical, and real-world studies showcase Genialis models for KRAS- and DDR-targeted therapies, including a predictive biomarker co-developed with Debiopharm Most drug ...

The MarketWatch News Department was not involved in the creation of this content. With a career dedicated to delivering firsts in medicine and innovating to find new ways to treat patients, ...

LAUSANNE, Switzerland & BOSTON--(BUSINESS WIRE)--Genialis, the RNA-biomarker company, and Debiopharm, a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards ...

At AACR 2026, the Genialis™ Supermodel–powered RNA survival model outperforms standard of care in real-world clinical data, establishing a scalable biomarker framework for ADC drug development ...

The program aims to deliver better guidance for physicians and ultimately improve outcomes for pancreatic cancer patients. BOSTON, October 02, 2025--(BUSINESS WIRE)--Genialis, the RNA biomarker ...

Genialis is a data science and drug discovery company focused on new ways to treat disease. Blending computational biology and AI-based methods, Genialis merges and models data at the intersection of ...

Tempus AI, Inc. TEM recently announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new ...

BOSTON & SAN DIEGO–(BUSINESS WIRE)–#ISO27001—Genialis, the RNA-biomarker company, today presented a poster on a new AI/ML classifier, Genialis™ krasID, that accurately predicts clinical benefit in a ...

Agreement allows both companies to define biomarkers within the DNA Damage Repair (DDR) biology space Genialis, the RNA-biomarker company, and Debiopharm, a privately-owned, Swiss-based ...